亚砷酸联合沙利度胺治疗骨髓增生异常综合征疗效分析

Analysis of the clinical effect of arsenious acid combine with thalidomide for treating myelodysplastic syndrome

目的探讨分析亚砷酸联合沙利度胺治疗骨髓增生异常综合征的临床疗效;方法选取56例初诊骨髓增生异常综合征(MDS)住院患者,随机分为实验组和对照组,给予不同的治疗方式,比较两组患者临床疗效和不良反应发生率。结果实验组患者临床疗效有效率为69.21%显著高于对照组患者42.31%,但不良反应发生率(30.77%)较对照组(65.38%)显著降低,差异均具有统计学意义(P<0.05)。结论亚砷酸联合沙利度胺较单一治疗沙利度胺骨髓增生异常综合征具有临床疗效高,不良反应发生率低的特点,是理想的治疗方法。

Objective To analysis the clinical effect of arsenious acid combine with thalidomide for treating myelodys- plastic syndrome. Methods 56 patients who first diagnosed with myelodysplastic syndrome （MDS） were selected and divided into the two groups, control group and experimental group. The two groups received different treatment, and then the clinical treatment effect and incidences of adverse effect were compared. Results The effective rate of experimental group （69.21%） was higher than the control group （42.31%）, and the incidences of adverse effect of the experimental （30.77%） was lower than the control group （65.38%） ,and the differece are statistically sig- nificant（ P 〈0.05 ）. Conclusion The arsenious acid combine with thalidomide was an effective treatment for myelo- dysplastic syndrome, and the low incidences of adverse effect were proven that it is an ideal treatment method.